EuMentis Therapeutics, Inc.
-
EuMentis is growing novel therapeutics with clinically validated mechanisms for the therapy of neurodevelopmental and neuropsychiatric situations
-
EuMentis plans to provoke Section 2 medical trials with EM-113 in autism spectrum dysfunction (ASD) and EM-221 in Tourette syndrome (TS) in 2nd half of this yr
-
Firm’s preclinical pipeline consists of novel fast-off NMDA receptor (NMDAR) modulators for therapy of traumatic mind damage (TBI) and different central nervous system (CNS) situations
BOSTON, Feb. 15, 2023 (GLOBE NEWSWIRE) — EuMentis Therapeutics Inc. (“EuMentis”), a privately held biopharmaceutical firm growing novel therapeutics for the therapy of neuropsychiatric and neurodevelopmental problems, together with its lead clinical-stage packages for ASD and TS, right now introduced the closing of $20 million of a focused $40 million Sequence B financing from a non-public household workplace. EuMentis is in lively dialogue with different traders to finish its Sequence B spherical.
EuMentis will use the proceeds from the $20 million financing to: 1) advance its lead medical candidate EM-113, a novel uncompetitive fast-off N-methyl-D-aspartate receptor (NMDAR) agonist, right into a Section 2 medical trial in a subset of ASD sufferers with elevated glutamate ranges within the mind, and a couple of) speed up the event of its earlier-stage fast-off NMDAR antagonist product candidates by way of IND submitting and completion of Section 1 medical trials. The lively ingredient in EM-113 has been proven beforehand in a placebo-controlled trial to be protected and efficient in pediatric ASD sufferers utilizing a proprietary imaging biomarker to pick responder sufferers. The entire Sequence B financing will allow EuMentis to conduct a further randomized, placebo-controlled Section 2 medical trial of EM-221, its best-in-class PDE10A inhibitor, in TS sufferers. Each medical research are anticipated to start out within the 2nd half of the yr.
Mark Tepper, Ph.D., Chief Govt Officer of EuMentis Therapeutics, acknowledged, “This financing represents a serious step ahead for EuMentis and permits us to advance our imaginative and prescient of turning into a pharmaceutical firm centered on neuropsychiatric and neurodevelopmental situations with excessive unmet want and few or no accredited therapeutic choices. EuMentis has a extremely skilled staff in place with deep experience and a confirmed monitor file of delivering transformative medicines. We imagine that EuMentis’ novel therapies have the potential to dramatically enhance the standard of lifetime of sufferers affected by autism, Tourette syndrome and traumatic mind damage, and different critical neuropsychiatric and neurodevelopment situations. We likewise look ahead to advancing EM-221 right into a randomized, placebo-controlled Section 2 medical research for Tourette syndrome with extra Sequence B capital.”
About EM-113 for Autism Spectrum Dysfunction
“Sufferers with autism spectrum dysfunction endure with issues of communication and habits, which, at current, can’t be successfully handled with any accredited medicines. A whole bunch of 1000’s of youngsters and their households are desperately in want of higher medical care to deal with this dysfunction. Based mostly on our novel biomarker-driven affected person choice technique derived from latest compelling medical information, EM-113 has the potential to be the primary remedy to deal with a core symptom of autism spectrum dysfunction. We’re delighted to have the ability to transfer rapidly into Section 2 with EM-113 within the second half of the yr,” mentioned Randall Marshall, M.D., Chief Medical Officer at EuMentis.
About EuMentis’ Preclinical, Subsequent-Era NMDAR Antagonists for Traumatic Mind Harm
Along with EM-113, EuMentis is growing novel, next-generation NMDAR antagonist product candidates with fast-off kinetics essential for minimizing uncomfortable side effects typically seen with different NMDAR antagonists like ketamine and dizocilpine (MK-801). Supported by its lately introduced $3 million grant award from the U.S. Division of Protection, EuMentis is evaluating these product candidates in preclinical research utilizing a big animal mannequin for traumatic mind damage in 2023 and plans to pick a lead candidate for TBI and advance it into Section 1 research in 2024.
About EM-221 for Tourette Syndrome
Kids and adults with TS expertise involuntary repetitive actions, vocalize sounds or phrases that they can not management, and sometimes wrestle with different critical neuropsychiatric situations. Excessive ranges of the neurotransmitter dopamine are believed to trigger the undesirable actions and vocalizations that characterize TS. EM-221 is designed to exactly modulate dopaminergic mind circuits implicated in TS.
Dr. Marshall acknowledged, “As a result of its mechanism of motion is very particular to the mind’s motion facilities, we count on EM-221 to have a way more favorable security profile than antipsychotics, that are at present accredited for Tourette syndrome, however are related to critical and typically long-term uncomfortable side effects. A protected and efficient drug to deal with TS would symbolize a serious advance for sufferers.”
About EuMentis
EuMentis Therapeutics Inc. is a privately held medical stage pharmaceutical firm centered on the event and commercialization of novel therapeutics to deal with neuropsychiatric and neurodevelopmental situations with excessive unmet want. The corporate’s most superior product candidate, EM-221, is a best-in-class oral PDE10A inhibitor designed to modulate the dopamine D2 pathway particularly within the striatum. EuMentis plans to provoke a Section 2 research of EM-221 for the therapy of Tourette syndrome within the second half of 2023. EuMentis can be growing EM-113, an uncompetitive fast-off NMDA receptor antagonist for the therapy of autism spectrum dysfunction sufferers with elevated mind glutamate ranges as decided by utilizing its proprietary biomarker affected person choice technique. EuMentis can be increasing its pipeline by way of the event of novel fast-off NMDAR antagonists for therapy of a number of situations through which elevated glutamate ranges contribute to the pathophysiology, together with traumatic mind damage (TBI), at current funded by an award from the USA Division of Protection, autism, and different neuropsychiatric and neurodevelopmental situations. EuMentis was based in 2019 with the mission to develop novel therapies to enhance the standard of lifetime of sufferers affected by central nervous system problems.
For extra data, please go to www.EuMentisTx.com and join with us on LinkedIn.
Media/Investor Contact:
Liz Melone
EuMentis Therapeutic Inc.
1 617-256-6622
liz@melonecomm.com
